About
Deliver Biosciences develops a nanoparticle-based delivery platform enabling the genetic engineering of cells in vivo to create scalable cell and gene therapies, with an initial focus on cancer immunotherapy using in vivo CAR-T cell programming.
Explore Deliver Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.